Varespladib for COVID-19: real-time analysis

Download Image

Post

c19early.org

Varespladib for COVID-19

1 study with 18 patients

Serious outcome risk

Varespladib

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Varespladib studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−120%

Mortality (1)−120%

RCTs (1)−120%

Late (1)−120%

00.511.5+

← Varespladib
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Nov 22 2022	Lickteig et al., NCT04969991	A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2
Nov 22 2022	120% higher mortality (p=1), 240% higher ventilation (p=1), and 240% higher progression (p=1). Very small early terminated RCT showing no significant differences with varespladib treatment.